ClinicalTrials.gg
RecruitingNCT07242352ADAPTelaUpdated Aug 7, 2026

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

A Phase 3 interventional study of Elacestrant and Standard-of-care endocrine treatment in Breast Cancer and HR+/HER2- Breast Cancer, sponsored by Women's Cancer Study Group GmbH. Recruiting at 33 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Women's Cancer Study Group GmbH · Phase 3, Interventional, and Treatment

How we know · 4 judgments

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,520
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies testing elacestrant in Breast Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. elacestrant · Breast Neoplasms.

Planned enrollment
2nd of 24
1,520 · median 72
Started
2026
with 5 others
Phase 3
4 of 24
2 open now
Primary completion
2033-09
later than 17 of 17 live
Registered
18th of 24
by date

Among the 24 studies testing elacestrant in Breast Neoplasms, this one is the 2nd largest by planned enrollment, is one of 6 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 17 of the 17 other live ones, and was the 18th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 24 studies testing elacestrant in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About elacestrant

elacestrant: first FDA approval 2023 (ORSERDU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing elacestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

In this clinical trial, the Sponsor plans to investigate whether patients with HR+/HER2- eBC identified during routine clinical assessments and treatments as having intermediate to high-risk (based on Oncotype DX® or similar tests and on response assessment to 2-6 weeks of preoperative ET) achieve a survival benefit from an initial 5-years use of elacestrant (with or without a CDK 4/6 inhibitor) followed by SoC ET for further 0-2.5 years in comparison to at least 5 up to 7.5 years SoC ET therapy (+/- CDK4/6 inhibitor).

Based on several studies in the metastatic setting, it is reasonable to assume that the adjuvant use of elacestrant with or without CDK 4/6 inhibitors will prevent or delay the activation of mechanisms conferring resistance to ET (e.g., ESR1 mutations).

Read the detailed description

Patients with hormone-receptor positive/HER2-negative (HR+/HER2-) early breast cancer (eBC) remain at risk of recurrence for many years after diagnosis. Current guidelines provide treatment recommendations depending on stage, histological grade, and menopausal status. However, patients with a high-risk HR+/HER2- eBC are at need for more efficacious treatment.

Several new strategies are currently investigated in patients diagnosed with high-risk HR+/HER2- eBC, including extending the duration of adjuvant endocrine therapy (ET), addition of ovarian function suppression (OFS) in case of premenopausal patients, and intensification of adjuvant ET by use of new therapies, such as cyclin-dependent kinase (CDK) 4/6 inhibitors. Moreover, development of algorithms incorporating not only clinical variables, but also key tumor biological variables such as Oncotype DX®/Recurrence Score (RS) or Mammaprint®, and possibly dynamic variables such as ET-response measured by Ki-67 after 2-6 weeks of preoperative standard endocrine induction therapy, could be of immense importance for risk estimation and subsequently optimization of therapy in intermediate to high-risk patients.

Several retrospective studies have shown that Oncotype DX® or other genomic tests are informative regarding prediction of treatment benefit in HR+/HER2- eBC. Therefore, use of RS instead of mostly relying on histological grade provides stronger prognostic and predictive information.

Further, characterization of ET-response has shown to provide important prognostic information in early HR+/HER2- eBC beyond clinical and genomic markers, as shown in the WSG-ADAPT-HR+/HER2-, ALLIANCE, and POETIC trials. The endocrine response has therefore become part of the ESMO guidelines as a prognostic factor.

The combination of classical prognostic markers with genomic assessments (e.g., Oncotype DX®) and endocrine response seems to be the most promising tool for identification of patients with significant relapse risk despite of standard ET and/or chemotherapy.

Remarkably in the 5-year analysis of the WSG-ADAPT-HR+/HER2- trial, ET-responders with RS >25 were shown to have more favorable survival than ET-non-responders, despite of higher pCR-rates in a subset of neoadjuvant chemotherapy (NACT)-treated patients. Therefore, patients with high genomic or clinical risk and/or ET-non responders with RS >25 with intermediate clinical risk are at need for alternative, more efficacious treatment approaches.

Optimal ET treatment in patients with intermediate-risk stage I-II disease but enhanced relapse risk remains unclear despite of the significant positive impact of Ribociclib on iDFS in stage II-patients demonstrated in NATALEE (NCT03701334).

The ADAPTcycle trial, based on the positive results for CDK 4/6 inhibitors in the adjuvant setting as shown in the MonarchE and NATALEE trials [12], is currently investigating whether replacing chemotherapy by an ET-CDK 4/6 based approach could be a better option for particular subgroups which are identified by combination of clinical and genomic risk and ET-responder status.

Moreover, the ongoing ADAPTlate trial investigates the impact of abemaciclib if added to standard ET in intermediate to high-risk HR+/HER2- eBC given immediately or within the first 2-6 years after completion of primary therapy.

Elacestrant is a novel, nonsteroidal, oral, selective oestrogen receptor degrader (SERD) that inhibits oestradiol-dependent gene transcription downstream of ER, including its mutated receptor variants, which is associated with endocrine resistance as demonstrated in phase I-trials [13]. Therefore, adjuvant use of SERDs may be beneficial in preventing ET resistance mechanisms.

In the phase III-trial EMERALD (NCT03778931), elacestrant improved PFS vs SoC in patients with metastatic HR+/HER2- breast cancer previously treated with ET in combination with a CDK4/6 inhibitor, especially in those harboring an ESR1-mutation. Also, according to EMBER-3 data in the metastatic setting, the use of SERDs in combination with standard CDK 4/6 inhibitors in patients with stage II-disease may be particularly effective across mutational profiles.

Interestingly, other SERDs were shown to yield a PFS benefit specificity in subgroups with mutated ESR1 variants and appear to require a combination with CDK 4/6 inhibitors to improve survival in wild-type ESR1 receptors, as demonstrated in the EMBER-3 trial.

Elacestrant is also under investigation in eBC. The phase I trial ELIPSE (NCT04797728) in postmenopausal women with early-stage (stage cT1-3, N0), ER-positive, HER2-negative breast cancer investigates 400 mg of elacestrant daily for four weeks in the neoadjuvant setting. The trial's primary outcome is proliferation arrest, defined as a Ki-67 level of ≤ 2.7%, in the surgical specimens collected after the end of trial treatment. Furthermore, the EORTC-2129-BCG (TREAT ctDNA, NCT05512364) is a phase III trial in pre- and postmenopausal women and men with high-risk early-stage ER-positive, HER2-negative breast cancer, and circulating tumor DNA (ctDNA) relapse. ctDNA-positive patients identified during the eligibility assessment, with no evidence of distant metastasis, will be randomized to receive either SoC endocrine treatment or elacestrant; the trial's primary endpoint is distant metastasis-free survival. However, this trial focuses on the populations at a high risk of recurrence, that is, stage IIB or stage III disease and completion of adjuvant chemotherapy or patients with at least four cycles of neoadjuvant chemotherapy and residual tumor at surgery of ≥ 1cm (≥ypT1c) or axillary node-positive (ypN+). Therefore, the information provided by the EORTC-2129-BCG trial on the activity of elacestrant in patients with intermediate-risk stage I-II disease will be limited.

03

Conditions studied

  • Breast Cancer
  • HR+/HER2- Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All patients, independent from gender
  2. Patient must be ≥18 years at diagnosis
  3. The patient must be capable of giving and be willing and able to comply with the requirements and restrictions in this protocol and accessible for treatment and follow-up
  4. Sign informed consent prior to any study-specific procedures.
  5. confirmed unilateral, primary invasive carcinoma of the breast Note: bilateral, multicentric, or multifocal carcinoma may only be included after consultation of Sponsor.
  6. Histologically confirmed diagnosis of primary hormone-receptor-positive (HR+) (i.e., oestrogen-receptor (ER) ≥ 10% and progesterone-receptor PR ≥ 10%) early breast cancer by local laboratory Note: ER positive according to ASCO / AGO Guidelines, ER 1-10% (low) is not defined as HR+.
  7. Patient has -negative breast cancer defined as a negative in-situ hybridization test or an IHC status of 0, 1+, or 2+, if IHC is 2+, a negative in-situ hybridization (FISH, CISH, or SISH) test is required (based on the most recently analysed tissue sample and all tested by a local laboratory).
  8. No evidence of distant (confirmed by CT thorax / abdomen, X-ray chest, ultrasound liver, bone scan, or PET-CT, respectively, performed within clinical routine).
  9. High genomic risk assessment within clinical routine (Oncotype DX® preferred; In those cases, where Oncotype Dx® is not possible in clinical routine, Oncotype Dx® should be assessed retrospectively after inclusion of the patient and as a study specific measure, provided sufficient tumour tissue from primary diagnosis is available.)
  10. 10. Completed 2-6 weeks of endocrine induction treatment and Ki-67 response assessment Note: 2-4 weeks recommended, up to 6 weeks allowed. Endocrine induction is highly recommended, but if endocrine induction therapy could not be performed or ET response is not representative, clinical factors should be used.
  11. 11. Completed (neo) chemotherapy, if applicable
  12. Completed radiotherapy, if applicable
  13. Patient meets any of the following three conditions at end of primary treatment (including endocrine induction treatment, /surgery, and if necessary, chemotherapy and radiotherapy and up to 12 months standard-of-care endocrine treatment, excluding previous treatment > 4 weeks with any SERD):

    Pathological Stage * Genomical High-Risk (Oncotype Dx®)** Age Clinical High-Risk Factors Stage I T1 N0

    RS>25 Any age High risk (≤ 1 factor applies):

    • ET non-response (post ET Ki-67 >10%)***
    • No Chemotherapy
    • G3 or PR negative and Ki-67 >25%***
    • Non-pCR after NACT*

    RS 16-25 Age \<50 High risk (≤ 1 factor applies):

    • ET non-response (post ET Ki-67 >10%)***
    • No Chemotherapy
    • G3 or PR negative and Ki-67 >25%***
    • Non-pCR after NACT* Any genomic risk Any age G3 and Ki-67>40%

    Stage IIa with T2 N0

    RS 0-25 Age>50 High risk (≤ 1 factor applies):

    • ET non-response (post ET Ki-67 >10%)***
    • G3 and Ki-67>40%
    • G3 or PR negative and Ki-67 >25%***
    • Non-pCR after NACT*

    RS 0-15 Age\<50 No chemotherapy AND high risk (≤ 1 factor applies):

    • ET non-response (post ET Ki-67 >10%)***
    • G3 and Ki-67>40%
    • G3 or PR negative and Ki-67 >25%***
    • Non-pCR after NACT*

    RS 16-25 Age\<50 No chemotherapy, AND/OR high risk (≤ 1 factor applies):

    • ET non-response (post ET Ki-67 >10%)***
    • G3 and Ki-67>40%
    • G3 or PR negative and Ki-67 >25%***
    • Non-pCR after NACT*

    RS >25 Any age Any clinical risk

    Any genomic risk Any age G3 and Ki-67 >40%

    Stage IIa with T1 N1, G1-2

    RS 0-25 Age>50 High risk (≤ 1 factor applies):

    • ET non-response (post ET Ki-67 >10%)***
    • PR negative and Ki-67 >25%***
    • Non-pCR after NACT*
    • 3 positive LN

    RS 0-25 Age \<50 No chemotherapy, AND/OR high risk (≤ 1 factor applies):

    • ET non-response (post ET Ki-67 >10%)***
    • PR negative and Ki-67 >25%***
    • Non-pCR after NACT*
    • 3 positive LN

    RS>25 Any age Any clinical risk

    Stage IIb with T3 N0 or T2 N1, G1-2 Any genomic risk Any age Any clinical risk

    * In patients treated by neoadjuvant chemotherapy, clinical stage should be used for inclusion

    ** In stage I-IIa and N0 patients with unknown genomic risk prior to inclusion, Oncotype Dx® Test should be performed on untreated tumour tissue within clinical routine.

    Results of other genomic tests, if already performed within the clinical routine, may be considered. In such cases, inclusion is only possible if clinical high-risk criteria apply and after consultation with sponsor.

    In those cases, where Oncotype Dx® is missing from clinical routine and in the N1-situation, Oncotype Dx® should be assessed retrospectively after inclusion of the patient and as a study specific measure, provided sufficient tumour tissue from primary diagnosis is available.

    *** Use of clinical factors is recommended in patients with unknown or not representative ET response.

  14. No for adjuvant SoC endocrine treatment
  15. No contraindication for elacestrant treatment
  16. No contraindication for ribociclib treatment, if medically indicated, and adequate time for inducers/inhibitors and time-prolonging drugs is given
  17. Tumour block for central pathology review (core biopsy of initial diagnosis and biopsy/surgery sample of definite surgery), if available
  18. Performance Status ≤ 1 or Index ≥ 80%
  19. Laboratory requirements (female and male patients, not older than 14 days prior to date of informed consent)

    • ≥ 1.5 × 109/L,
    • ≥ 100 × 109/L,
    • ≥ 9.0 g/dL,
    • ≤ 1.5,
    • serum creatinine \< 1.5 × OR clearance ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN
    • total \< ULN, except for patients with Gilbert's Syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN,
    • (AST) \< 2.5 × ULN,
    • alanine transaminase (ALT) \< 2.5 × ULN,
    • Screening lipid panel fasting levels: total cholesterol ≤400 mg/dL AND/OR triglycerides \<500 mg/dL.

    Note: Patients with lipid panel fasting levels NOT meeting the above criteria may consider initiating therapy for lipid management per local guidelines and will be allowed to be included once the lipid levels meet the inclusion criteria.

  20. Clinical assessments:

    • normal within 6 weeks prior to randomization (QTcF interval at screening \<450msec using Fridericia's correction, mean resting heart rate 50-90 bpm)
  21. Ability to swallow tablets

A. Female patients of at inclusion must have a negative pregnancy test (serum) and additionally fulfil either one of the following conditions:

  • surgically sterile,
  • or carry a non-hormone releasing intrauterine device (combined with a barrier method),
  • or having received tubal ligation/occlusion (combined with a barrier method),
  • or using a highly effective contraceptive method from the time they sign consent, during participation in the study until end of study, at least 4 months (120 days) after the last dose of ELA, and for at least 21 days after the last dose of RIBO) to prevent pregnancy; ova donation or preservation is also not allowed within this time frame
  • Total/true abstinence: When the patient refrains from any form of sexual intercourse and this is in line with their usual and/or preferred lifestyle; this must continue from the time they sign consent, during participation in the study until end of study, at least 4 months (120 days) after the last dose of ELA, and for at least 21 days after the last dose of RIBO) to prevent pregnancy;
  • Vasectomised sexual partner (with participant assurance that partner received post-vasectomy confirmation of azoospermia) combined with a barrier method or sexual partner with bilateral orchiectomy.
  • Hormonal contraception is not acceptable. B. Male patients must either be
  • surgically sterile
  • or using a highly effective method of contraception from the time they sign consent, during participation in the study until end of study, at least 4 months (120 days) after the last dose of ELA, and for at least 21 days after the last dose of RIBO) to prevent pregnancy in a partner; sperm donation or preservation is also not allowed within this time frame
  • Male patients who intend to be sexually active with a woman of childbearing potential, must use a condom plus spermicide from the time they sign consent, during participation in the study until end of study, at least 4 months (120 days) after the last dose of ELA, and for at least 21 days after the last dose of RIBO) to prevent pregnancy in a partner;
  • Highly effective methods of contraception should be considered in female partners of men taking elacestrant and/or ribociclib who are of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  1. Known to any of the compounds or incorporated substances of the IMPs
  2. Prior with a disease-free survival of \<5 years, except curatively treated basalioma of the skin or pTis of the cervix uteri
  3. Any history of invasive cancer within the last 10 years Note: adequately treated, basal or squamous-cell skin carcinoma, non-melanomatous skin cancer, curatively resected cervical cancer, and contralateral DCIS treated by mastectomy (contralateral in relation to current invasive breast cancer diagnosis) are excepted. Previous ipsilateral DCIS, irrespective of treatment, is excluded!
  4. Patient with distant of breast cancer beyond regional lymph nodes.
  5. Concurrent treatment with cytotoxic agents for any non-oncological reason unless clarified with sponsor
  6. Concurrent treatment with other experimental drugs
  7. Participation in another interventional clinical trial with or without any , not marketed drug within 30 days or 5 half-lives of the respective drug, whichever is longer, prior to study entry. In case of other interventional trial contact Sponsor.
  8. Previous treatment (>4 weeks) with any SERD
  9. Concurrent pregnancy; patients of or potentially childbearing partners of male patients must implement a highly effective (less than 1% failure rate) non-hormonal measures during the study treatment
  10. Breast feeding woman
  11. Use of oral, transdermal, injected, or implanted hormonal methods of contraception as well as hormonal replacement therapy (oestrogen or progesterone).
  12. Reasons indicating risk of poor compliance
  13. Patient not able to consent
  14. Patient has not recovered from clinical and laboratory acute toxicities related to prior anticancer therapies to version 5.0 Grade ≤ 1.
  15. Severe and relevant co-morbidity that would interact with the application of endocrine treatment of any kind or the participation in the study
  16. For patients planned for ribociclib treatment: , uncontrolled heart disease and/or cardiac repolarization abnormality, including any of the following:

    • history of myocardial infarction (MI), angina pectoris, symptomatic pericarditis, or coronary artery bypass graft (CABG) within 6 months prior to study entry,
    • documented cardiomyopathy,
    • (LVEF) \< 50 % as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO),
    • long syndrome, family history of idiopathic sudden death, congenital long QT syndrome, or any of the following:

      • risk factors for Torsades de Pointe (TdP, polymorphic ventricular tachycardia in patients with long QT syndrome) including uncorrected hypokalaemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/ symptomatic bradycardia,
      • concomitant medications with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued or replaced by safe alternative medication (e.g., within 5 half-lives or 7 days prior to starting study drug),
      • inability to determine the QTcF interval,
      • clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), complete left-bundle branch block, high-grade AV block (e.g., bi-fascicular block, Mobitz type II, and 3rd-degree AV block),
      • systolic blood pressure (SBP) > 160 or \< 90 mmHg.
  17. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome, or small-bowel resection).
  18. Uncontrolled infection requiring i.v. antibiotics, antivirals, or antifungals
  19. Active primary immunodeficiency, known (HIV) infection. Patients should be tested for HIV prior to randomization if required by local regulations or ethics committee (EC). Patients who test positive for HIV-antibody are excluded.
  20. Patient has known active hepatitis-B-virus () or hepatitis-C-virus () infection. Screening for HBV or HBC-infection and testing for hepatitis-B or -C is highly recommended according to current valid (local) clinical guidelines, but neither part of the interventional study procedures, nor required for enrolment.
  21. Patient has received within 30 days prior to randomization.
  22. Patient was submitted to an institution by virtue of an order of a court or a governmental authority must be excluded from participation.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,520 participants (estimated)

Study arms

  • Experimental
    Elacestrant upfront (ELA)

    Patients will be treated with elacestrant (ELA) for 5 years. In case further treatment, e.g., CDK4/6 inhibitors, is indicated, ribociclib (RIBO) may be added for 3 years in parallel

    Drug: Elacestrant

  • Active comparator
    Standard-of-care endocrine treatment (SoC-ET)

    Patients will be treated with SoC ET for 5-10 years. In case further treatment, e.g., CDK4/6 inhibitors, is indicated, this may be added according to SoC and per investigator´s discretion.

    Drug: Standard-of-care endocrine treatment

Interventions

  • Elacestrant, a tetrahydronaphthalene compound, is a potent, selective, and orally active oestrogen receptor-α (ERα) antagonist and degrader.

    Also known as: ORSERDU

  • DrugStandard-of-care endocrine treatment

    SoC ET comprises all endocrine treatments authorized for the condition under review. The choice is made upon investigator´s discretion.

This study also gives RibociclibStudies of RibociclibRibociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. 5-year invasive disease-free survival (iDFS)

    iDFS after 5 years, compared between patients randomized to adjuvant elacestrant (+/-CDK4/6i) or SOC ET (+/- CDK4/6i)

    Time frame: iDFS 5 years

Secondary outcomes

  1. 5-year distant disease-free survival (dDFS)

    5-year dDFS

    Time frame: dDFS 5 years

  2. 5-year relapse-free survival (RFS)

    5-year RFS

    Time frame: RFS 5 years

  3. 5-year DCIS disease-free survival (DFS-DCIS)

    5-year DFS-DCIS

    Time frame: DFS-DCIS 5 years

  4. 5-year invasive breast cancer-free survival (IBCFS)

    5-year IBCFS

    Time frame: IBCFS 5 years

  5. 5-year locoregional relapse-free survival (LRFS)

    5-year LRFS

    Time frame: LRFS 5 years

  6. 5-year overall survival (OS)

    5-year OS

    Time frame: OS 5 years

07

Study locations

28 of 33 sites recruiting
  • Universitaetsklinikum Mannheim GmbH Frauenklinik
    Mannheim, Baden-Wurttemberg 68167, Germany
    Recruiting
    • Mattea Reinisch, Priv. Doz. Dr. med. · Contact
    • Anne-Valérie Keller, MSc · Contact
    • Mattea Reinisch, Priv. Doz. Dr. med. · Principal investigator
    • Frederik Marmé, Prof. Dr. med. · Sub investigator
  • Universitaetsklinikum Tuebingen AöR Frauenklinik
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
    • Andreas Hartkopf, Prof. Dr. med · Contact
    • Bettina Walter-Thorwart · Contact
    • Andreas Hartkopf, Prof. Dr. med · Principal investigator
    • Lea Lousie Volmer, Dr. med · Sub investigator
  • Klinikum Esslingen GmbH Klinik für Frauenheilkunde und Geburtshilfe
    Esslingen am Neckar, Baden-Wüttemberg 73730, Germany
    Recruiting
    • Alexander Hein, Prof. Dr. med · Contact
    • Jana Shabbir · Contact
    • Alexander Hein, Prof. Dr. med. · Principal investigator
    • Bettina Braun, Dr. med · Sub investigator
  • Praxis Fuer Interdisziplinaere Onkologie And Haematologie GbR
    Freiburg im Breisgau, Baden-Wüttemberg 79110, Germany
    Recruiting
    • Matthias Zaiss, Dr.med · Contact
    • Sabine Souchon · Contact
    • Matthias Zaiss, Dr.med · Principal investigator
    • Patrick Marschner, Dr.med · Sub investigator
  • Klinikum St Marien Amberg Klinik für Frauenheilkunde und Geburtshilfe
    Amberg, Bavaria 92224, Germany
    Recruiting
    • Tanja Hauzenberger, Dr. med. · Contact
    • Jacqueline Roy · Contact
    • Tanja Hauzenberger, Dr. med. · Principal investigator
    • Thomas Papathemelis, Prof. Dr. med. · Sub investigator
  • Haematologie-Onkologie im Zentrum MVZ GmbH
    Augsburg, Bavaria 86150, Germany
    Not yet recruiting
    • Bernhard Heinrich, Dr. med. · Contact
    • Nina Wittmann · Contact
    • Bernhard Heinrich, Dr. med. · Principal investigator
    • Markus Bangerter, Prof. Dr. med. · Sub investigator
  • Klinikum der Universitaet Muenchen AöR Frauenheilkunde und Geburtshilfe
    München, Bavaria 80336, Germany
    Not yet recruiting
    • Nadia Harbeck, Prof. Dr. med · Contact
    • Beate Rank · Contact
    • Nadia Harbeck, Prof. Dr. med · Principal investigator
    • Rachel Würstlein, Prof. Dr. med · Sub investigator
  • Rotkreuzklinikum Muenchen gGmbH Interdisziplinäres Brustzentrum
    München, Bavaria 80637, Germany
    Recruiting
    • Michael Braun, Prof. Dr. med · Contact
    • Harry Reisch · Contact
    • Michael Braun, Prof. Dr. med. · Principal investigator
    • Claus Hanusch, Dr. med · Sub investigator
  • Haematologisch Onkologische Schwerpunktpraxis
    Würzburg, Bavaria 97080, Germany
    Recruiting
    • Dominik Pretscher, Dr. med. · Contact
    • Janina Cummins · Contact
    • Dominik Pretscher, Dr. med. · Principal investigator
    • Björn Schöttker, Dr. med. · Sub investigator
  • Medical University Of Lausitz Carl Thiem Frauenklinik
    Cottbus, Brandenburg 03048, Germany
    Recruiting
    • Nikola Bangemann, Dr. med · Contact
    • Amelia Simon · Contact
    • Nikola Bangemann, Dr. med · Principal investigator
  • Mammazentrum Hamburg MVZ GbR
    Hamburg, Free and Hanseatic City of Hamburg 20357, Germany
    Not yet recruiting
    • Christian Schem, Prof. Dr. med · Contact
    • Silke Kassner · Contact
    • Christian Schem, Prof. Dr. med · Principal investigator
    • Anne-Sophie Adam, Dr. med · Sub investigator
  • Hämatologische Onkologische Praxis im Medicum
    Bremen, Free Hanseatic City of Bremen 28209, Germany
    Recruiting
    • Ralf Meyer, Dr. med · Contact
    • Heike Munzinger · Contact
    • Ralf Meyer, Dr. med · Principal investigator
    • Carsten Schreiber, Dr. med · Sub investigator
  • Gesundheitszentrum Wetterau gGmbH Gynäkologische Ambulanz
    Bad Nauheim, Hesse 61231, Germany
    Recruiting
    • Carolin Hammerle, Dr. med. · Contact
    • Anne Groß · Contact
    • Carolin Hammerle, Dr. med. · Principal investigator
    • Ulrich Groh, Dr. med. · Sub investigator
  • Centrum für Hämatologie und Onkologie Bethanien
    Frankfurt am Main, Hesse 60389, Germany
    Recruiting
    • Hans Tesch, Prof. Dr. med · Contact
    • Karin Baumbach · Contact
    • Hans Tesch, Prof. Dr. med · Principal investigator
    • Dorothee Gebhart, Dr. med. · Sub investigator
  • Elisabeth Krankenhaus GmbH Brustzentrum
    Kassel, Hesse 34117, Germany
    Recruiting
    • Sabine Schmatloch, Dr. med. · Contact
    • Ivonne Kurzhals · Contact
    • Sabine Schmatloch, Dr. med. · Principal investigator
    • Jan Christoph Stassek, Dr. med. · Sub investigator
  • Medizinische Hochschule Hannover Klinik für Frauenheilkunde und Geburtshilfe Brustzentrum
    Hanover, Lower Saxony 30625, Germany
    Recruiting
    • Tjoung-Won Park- Simon, Prof. Dr. med · Contact
    • Sylvia Klug · Contact
    • Tjoung-Won Park- Simon, Prof. Dr. med · Principal investigator
  • Gemeinschaftspraxis Frauenärzte am Bahnhofsplatz
    Hildesheim, Niedersachen 31134, Germany
    Recruiting
    • Christoph Uleer, Dr. med · Contact
    • Andrea Meyer-Kühn · Contact
    • Christoph Uleer, Dr. med · Principal investigator
    • Jasmon Poufard, Dr. med · Sub investigator
  • Klinik Dr. Hancken GmbH
    Stade, Niedersachen 21680, Germany
    Recruiting
    • Wiebke Timm, Dr. med · Contact
    • Birte Rahn · Contact
    • Wiebke Timm, Dr. med · Principal investigator
    • Britta Heitmann, Dr. med · Sub investigator
  • Johanniter GmbH Onkologisches Zentrum
    Bonn, North Rhine-Westphalia 53113, Germany
    Recruiting
    • Yon-Dschun Ko, Prof. Dr. med. · Contact
    • Ilona Klesewetter · Contact
    • Yon-Dschun Ko, Prof. Dr. med. · Principal investigator
    • Jakob Reinke · Sub investigator
  • Marienhospital Bottrop gGmbH Klinik für Gynäkologie und Geburtshilfe
    Bottrop, North Rhine-Westphalia 46236, Germany
    Recruiting
    • Hans-Christian Kolberg, Prof. Dr. med · Contact
    • Katharina Freienstein · Contact
    • Hans-Christian Kolberg, Prof. Dr. med · Principal investigator
    • Leyla Akpolat-Basci, Dr. med · Sub investigator
  • Klinikum Dortmund gGmbH Frauenklinik Dortmund
    Dortmund, North Rhine-Westphalia 44137, Germany
    Recruiting
    • Claudia Biehl · Contact
    • Songül Binli · Contact
    • Claudia Biehl · Principal investigator
  • Universitaetsklinikum Duesseldorf AöR Klinik für Frauenheilkunde und Geburtshilfe
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Recruiting
    • Tanja Fehm, Prof. Dr. med · Contact
    • Nadia Stamm · Contact
    • Tanja Fehm, Prof. Dr. med. · Principal investigator
    • Eugen Ruckhäberle, Prof. Dr. med · Sub investigator
  • St.-Antonius-Hospital gGmbH Klinik für Hämatologie und Onkologie
    Eschweiler, North Rhine-Westphalia 52249, Germany
    Recruiting
    • Peter Staib, Prof. Dr. med · Contact
    • Katja Ohlen · Contact
    • Peter Staib, Prof. Dr. med · Principal investigator
    • Matthias Humberg · Sub investigator
  • St. Barbara-Klinik Hamm GmbH Brustzentrum
    Hamm, North Rhine-Westphalia 59073, Germany
    Recruiting
    • Wlodzimierz Badur, Dr. med · Contact
    • Gabriele Kerkmann · Contact
    • Wlodzimierz Badur, Dr. med · Principal investigator
    • Claudia Strunk · Sub investigator
  • Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus
    Mönchengladbach, North Rhine-Westphalia 41061, Germany
    Recruiting
    • Katja Krauß, Dr. · Contact
    • Carolin Sydlik · Contact+496141
    • Katja Krauß, Dr. · Principal investigator
    • Iris Scheffen, Dr.med · Sub investigator
  • Stiftung Mathias-Spital Rheine Brustzentrum
    Rheine, North Rhine-Westphalia 48431, Germany
    Recruiting
    • Mathias Füller, Dr. med. · Contact
    • Denise Ernst · Contact
    • Dr. med. Mathias Füller, Dr. med. · Principal investigator
    • Laura Heitmann, Dr. med. · Sub investigator
  • MKS St. Paulus GmbH Märkisches Brustzentrum
    Schwerte, North Rhine-Westphalia 58239, Germany
    Recruiting
    • Sarah Wetzig · Contact
    • Kristin Backhaus · Contact
    • Sarah Wetzig · Principal investigator
    • Asja Sborowski, Dr. med · Sub investigator
  • Praxisnetz Hämatologie / internistische Onkologie
    Troisdorf, North Rhine-Westphalia 53840, Germany
    Recruiting
    • Ernst Rodermann, Dr. med · Contact
    • Sylvia Gawor-Becker · Contact
    • Ernst Rodermann, Dr. med · Principal investigator
  • Marien-Hospital Witten Brustzentrum
    Witten, North Rhine-Westphalia 58452, Germany
    Recruiting
    • Monika Graeser, PD Dr. med · Contact
    • Anika Schmidt · Contact
    • Monika Graeser, PD Dr. med. · Principal investigator
    • Esther Sakina Valverde Duran · Sub investigator
  • Helios Universitaetsklinikum Wuppertal Landesfrauenklinik - Brustzentrum
    Wuppertal, North Rhine-Westphalia 42283, Germany
    Not yet recruiting
    • Vesna Bjelic-Radisic, Prof. Dr. · Contact
    • Manuela Smiljanic · Contact
    • Vesna Bjelic-Radisic, Prof. Dr · Principal investigator
    • Bianca Böning, Dr. med · Sub investigator
  • Klinikum Mutterhaus der Borromaeerinnen gGmbH
    Trier, Rhineland-Palatinate 54290, Germany
    Recruiting
    • Sebastian Jud, Prof. Dr. med · Contact
    • Natalja Frick · Contact
    • Sebastian Jud, Prof. Dr. med · Principal investigator
    • Katharina Simon, Dr. med · Sub investigator
  • HELIOS Klinikum Berlin-Buch GmbH Klinik für Gynäkologie und Geburtshilfe
    Berlin, State of Berlin 13125, Germany
    Not yet recruiting
    • Dr. med. Christine Mau · Contact
    • Katja Jungel · Contact
    • Christine Mau, Dr. med. · Principal investigator
    • Michael Untch, Prof. Dr. med. · Sub investigator
  • Staedtisches Klinikum Lueneburg gGmbH Brustkrebszentrum Lueneburg
    Lüneburg, 21339, Germany
    Recruiting
    • Peter Dall, Prof. Dr. med · Contact
    • Katja Zmarsly · Contact
    • Peter Dall, Prof. Dr. med · Principal investigator
    • Eric Boetel, Dr. med · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2033, 89 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 89 months is above that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Nov 21, 2025
StartActual
Apr 29, 2026
Primary completionEst.
Sep 30, 2033
CompletionEst.
Sep 30, 2033
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07242352
Lead sponsor
Women's Cancer Study Group GmbH
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Apr 29, 2026
Primary completion
Sep 30, 2033 (estimated)
Completion
Sep 30, 2033 (estimated)
Last update
Aug 7, 2026

Study contacts

Anja Braschoß
Contact
regulatory@wsg-online.com
004917682119153
Marina Mangold, Dr.
Contact
marina.mangold@wsg-online.com
00492161566 23-0
Peter Schmid, PHD Dr
principal investigator · Fliethstraße 112-114 41061 Moenchengladbach Germany
NAdia Harbeck, Prof Dr
principal investigator · Breast Centre, Dept. Obstetrics & Gynaecology and CCC Munich LMU University Hospital Munich Germany
Oleg Gluz, Prof Dr
principal investigator · Breast Centre, Evang. Bethesda-Hospital Moenchengladbach Germany
Sherko Kuemmel, Prof Dr
principal investigator · Breast Centre, Kliniken Essen Mitte Essen Germany
Monika Graeser, PD Dr
principal investigator · Breast Centre, Marien-Hospital Witten Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elacestrant

Start the discussion